Form 4: Aclaris Therapeutics COO Converts RSUs to Common Stock
Insider Transaction Report
Aclaris Therapeutics' President and COO, Hugh M. Davis, converted 18,675 restricted stock units into common stock.
Summary
- Hugh M. Davis, President and COO of Aclaris Therapeutics, Inc., reported the conversion of 18,675 Restricted Stock Units (RSUs) into 18,675 shares of the company's common stock.
- The transaction occurred on February 3, 2026.
- Following this conversion, Davis directly holds 45,425 shares of Aclaris Therapeutics common stock.
- He also retains 56,025 unvested Restricted Stock Units.
- The converted RSUs were part of a grant that vests in four equal installments on the first, second, third, and fourth anniversaries of February 3, 2025, subject to continuous service.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, representing a routine compensation and vesting transaction for a key executive, rather than a direct indicator of company performance or strategic shift.
Positives
- Hugh M. Davis, President and COO, increased his direct ownership of Aclaris Therapeutics common stock by 18,675 shares through the conversion of Restricted Stock Units, which aligns executive interests with shareholder value.
Future Outlook
The remaining 56,025 Restricted Stock Units will continue to vest in four equal annual installments from February 3, 2025, subject to continuous service of the reporting person.
Industry Context
StockSavvy.ai notes that RSU conversions are common compensation events for executives, aligning their interests with shareholders by increasing their direct equity stake in the company.
Stakeholder Impact
- Shareholders: Increased direct ownership by a key executive may be seen as a minor positive for alignment of interests between management and shareholders.
Next Steps
- Remaining 56,025 Restricted Stock Units will vest in future installments on the anniversaries of February 3, 2025.
Key Dates
| Date | Description |
|---|---|
| 02/03/2025 | Initial grant date for the Restricted Stock Units, from which vesting anniversaries are calculated. |
| 02/03/2026 | Date of RSU conversion transaction. |
| 02/05/2026 | Date the Form 4 was signed. |
Keywords
Aclaris Therapeutics, ACRS, insider transaction, Form 4, RSU conversion, stock ownership, Hugh M. Davis
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.